METASTATIC ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC ER-POSITIVE HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ER-POSITIVE HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC ER-POSITIVE HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to slow advanced breast cancer
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…
Matched conditions: METASTATIC ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Targeted pill combo could spare some breast cancer patients from chemo
Disease control OngoingThis phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigne…
Matched conditions: METASTATIC ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC